Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany

Abstract

Objectives:

An economic evaluation was conducted to assess the outcomes and costs as well as cost-effectiveness of the following grass-pollen immunotherapies: OA (Oralair; Stallergenes S.A., Antony, France) vs GRZ (Grazax; ALK-Abelló, Hørsholm, Denmark), and ALD (Alk Depot SQ; ALK-Abelló) (immunotherapy agents alongside symptomatic medication) and symptomatic treatment alone for grass pollen allergic rhinoconjunctivitis.

Methods:

The costs and outcomes of 3-year treatment were assessed for a period of 9 years using a Markov model. Treatment efficacy was estimated using an indirect comparison of available clinical trials with placebo as a common comparator. Estimates for immunotherapy discontinuation, occurrence of asthma, health state utilities, drug costs, resource use, and healthcare costs were derived from published sources. The analysis was conducted from the insurant’s perspective including public and private health insurance payments and co-payments by insurants. Outcomes were reported as quality-adjusted life years (QALYs) and symptom-free days. The uncertainty around incremental model results was tested by means of extensive deterministic univariate and probabilistic multivariate sensitivity analyses.

Results:

In the base case analysis the model predicted a cost-utility ratio of OA vs symptomatic treatment of €14,728 per QALY; incremental costs were €1356 (95%CI: €1230; €1484) and incremental QALYs 0.092 (95%CI: 0.052; 0.140). OA was the dominant strategy compared to GRZ and ALD, with estimated incremental costs of −€1142 (95%CI: −€1255; −€1038) and −€54 (95%CI: −€188; €85) and incremental QALYs of 0.015 (95%CI: −0.025; 0.056) and 0.027 (95%CI: −0.022; 0.075), respectively. At a willingness-to-pay threshold of €20,000, the probability of OA being the most cost-effective treatment was predicted to be 79%. Univariate sensitivity analyses show that incremental outcomes were moderately sensitive to changes in efficacy estimates. The main study limitation was the requirement of an indirect comparison involving several steps to assess relative treatment effects.

Conclusion:

The analysis suggests OA to be cost-effective compared to GRZ and ALD, and a symptomatic treatment. Sensitivity analyses showed that uncertainty surrounding treatment efficacy estimates affected the model outcomes.

• Rhinoconjunctivitis
• Immunotherapy
• Grass pollen
• Symptomatic medication
• OA
• Cost-effectiveness

Transparency

Declaration of funding

The study was funded by Stallergenes GmbH.

Declaration of financial relationships

The authors had complete access to all data and had final control over the content, review, and submission of this manuscript. Kirsten Y. Westerhout and Bram G. Verheggen have disclosed that they are employees of Pharmerit International, a company that was paid by Stallergenes to develop the manuscript. C. H. Schreder has disclosed that he is an employee of Stallergenes GmbH, Kamp-Lintfort, Germany. M. Augustin has disclosed he is a consultant to Stallergenes.

Acknowledgments

The authors would like to thank Christian Döring for his help on cost inputs.